Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

937
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
937
Seizures: Classification01:13

Seizures: Classification

2.1K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.1K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.6K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.6K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

925
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
925
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical Evidence for a Drug-Drug Interaction Between Cannabinol and Melatonin.

Basic & clinical pharmacology & toxicology·2024
Same author

A high seizure burden increases brain concentrations of specialized pro-resolving mediators in the Scn1a<sup>+/-</sup> mouse model of Dravet syndrome.

Prostaglandins & other lipid mediators·2024
Same author

Novel mouse model of alternating hemiplegia of childhood exhibits prominent motor and seizure phenotypes.

Neurobiology of disease·2024
Same author

Brain on Fire: How Brain Infection and Neuroinflammation Drive Worldwide Epilepsy Burden.

Epilepsy currents·2024
Same author

Fine mapping and candidate gene analysis of Dravet syndrome modifier loci on mouse chromosomes 7 and 8.

Mammalian genome : official journal of the International Mammalian Genome Society·2024
Same author

Fine Mapping and Candidate Gene Analysis of Dravet Syndrome Modifier Loci on Mouse Chromosomes 7 and 8.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Mar 24, 2026

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
11:54

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy

Published on: January 29, 2018

27.3K

KCNA2-Related Epileptic Encephalopathy.

Jennifer A Kearney1

  • 1Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Pediatric Neurology Briefs
|March 3, 2016
PubMed
Summary

Mutations in the KCNA2 gene are identified as a new cause of severe epilepsy. This discovery offers insights into the genetic basis of epileptic encephalopathy.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Epileptic encephalopathy is a group of severe epilepsy syndromes.
  • The genetic underpinnings of many epileptic encephalopathies remain poorly understood.

Purpose of the Study:

  • To identify novel genetic causes of epileptic encephalopathy.
  • To investigate the role of the KCNA2 gene in neurological disorders.

Main Methods:

  • Genetic analysis of patients with epileptic encephalopathy.
  • Functional studies of identified KCNA2 mutations.

Main Results:

  • Mutations in the KCNA2 gene were identified in patients with epileptic encephalopathy.
  • These mutations are associated with altered function of the KCNA2 potassium channel.
Keywords:
Dominant-Negative EffectEpilepsyKCNA2

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

4.1K
A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
06:58

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

Published on: July 12, 2021

5.8K

Related Experiment Videos

Last Updated: Mar 24, 2026

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
11:54

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy

Published on: January 29, 2018

27.3K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

4.1K
A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
06:58

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

Published on: July 12, 2021

5.8K

Conclusions:

  • Mutations in KCNA2 represent a novel genetic cause of epileptic encephalopathy.
  • Understanding the role of KCNA2 mutations can inform diagnosis and potential therapeutic strategies.